Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.31 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4351614 | 1.00 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL27849374 | 1.00 | SLC1A3 (0.46) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL5084435 | 0.84 | TDP1 (0.43) | SLC1A3SLC1A2SLC1A1TDP1OR51E2 | |
| SCHEMBL27833944 | 0.83 | TP53 (0.39) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL2035309 | 0.82 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL6871010 | 0.82 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL2031190 | 0.82 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL2031192 | 0.82 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL8101229 | 0.82 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1TDP1TP53 | |
| SCHEMBL2035310 | 0.82 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1TDP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102432466-B | Preparation method of aliskiren intermediate | WUHAN WUYAO PHARMACEUTICAL CO LTD | 2013-10-16 | — | — | CN | claimed |
| CN-102432466-A | Preparation method of aliskiren intermediate | WUHAN WUYAO PHARMACEUTICAL CO LTD | 2012-05-02 | — | — | CN | claimed |
| CN-102432466-B | Preparation method of aliskiren intermediate | WUHAN WUYAO PHARMACEUTICAL CO LTD | 2013-10-16 | — | — | CN | disclosed |
| CN-102432466-B | Preparation method of aliskiren intermediate | WUHAN WUYAO PHARMACEUTICAL CO LTD | 2013-10-16 | — | — | CN | disclosed |
| CN-102432466-A | Preparation method of aliskiren intermediate | WUHAN WUYAO PHARMACEUTICAL CO LTD | 2012-05-02 | — | — | CN | disclosed |
| CN-102432466-A | Preparation method of aliskiren intermediate | WUHAN WUYAO PHARMACEUTICAL CO LTD | 2012-05-02 | — | — | CN | disclosed |
| US-20090281103-A1 | Renin Inhibitors | MERCK CANADA INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| US-20050159460-A1 | Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease | ELAN PHARMACEUTICALS | 2005-07-21 | — | — | US | disclosed |
| EP-1450795-A1 | PEPTIDE ISOSTERES CONTAINING A HETEROCYCLE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003047576-A1 | PEPTIDE ISOSTERES CONTAINING A HETEROCYCLE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-0603309-A1 | PEPTIDE ISOTERS CONTAINING A HETEROCYCLE AS H.I.V. INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-06-29 | — | — | EP | disclosed |
| WO-1993005026-A1 | PEPTIDE ISOTERS CONTAINING A HETEROCYCLE AS H.I.V. INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159460-A1 | Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease | BACE1, APP, BACE2 | SLC1A3 2600/4885SLC1A2 2509/4885SLC1A1 2670/4885 |
| US-20090281103-A1 | Renin Inhibitors | REN, ACE, AGT | SLC1A3 4128/4885SLC1A2 4266/4885SLC1A1 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.